Introduction
Sarcoidosis is a chronic multisystemic granulomatous disorder of uncertain pathogenesis. 1 The reported incidence of lymphoma in patients with sarcoidosis is 5.5-11 times higher. 2 If we exclude 'sarcoid-like reactions' that occur either adjacent to the primary malignant site or next to its local drainage nodes in patients who do not fulfill the systemic sarcoidosis criteria, three types of sarcoidosis-lymphoma association can be distinguished. The first 'sarcoidosis-lymphoma syndrome' as described by Brincker is characterized by (i) the onset of sarcoidosis several years before diagnosis of lymphoma, (ii) the onset of sarcoidosis after 40 years of age and (iii) the more frequent association with Hodgkin's lymphoma. 3, 4 The second is sarcoidosis concurrent with lymphoma, in which the onset of sarcoidosis is coincidental within 1 year of the discovery of a patient' unsuspected cancer and vis-à-vis. 4 The third is the uncommon situation in which the onset of sarcoidosis follows the diagnosis of the lymphoma by at least 1 year. 5 However, very little data currently exist regarding these three types of association. To date, the largest published series included 17 patients, 3 whereas the largest literature review consisted of 79 cases. 5 Since the publication of these papers, only one recent large series focusing on sarcoidosis following the diagnosis of the lymphoma has been published. 6 Here, we report a retrospective multicentre cohort study of lymphoma cases associated with sarcoidosis. The aims of the study are to describe the characteristics of this association and to determine whether lymphoma has a better prognosis when associated with sarcoidosis.
Patients and methods

Identification and validation of exposed patients
Three criteria had to be met to include patients in this study: (i) clinical and paraclinical features consistent with sarcoidosis, (ii) histopathological analysis revealing non-caseating granuloma (except for patients with Lö fgren's syndrome, in whom the diagnosis of sarcoidosis did not require histological evidence) and (iii) biopsy-proven lymphoma in accordance with the World Health Organization 2008.
The exclusion criteria were other granulomatous disorders, 2 post-transplant lymphoproliferative disorder and sarcoid-like reactions.
We retrospectively reviewed the records of all patients, hospitalized in two hematology departments from 1999 to 2014 (University Hospital of Lyon and Léon Berard Center), using the institutional database of diagnosis coding (Programme de Médicalisation du Système d'Information).
No approval from the University of Lyon Institutional Review Board was required. Indeed, this retrospective study neither violated anyone's privacy nor did it lead to any intervention or treatment of the patients included. A strict adherence to the guidelines of the Declaration of Helsinki was observed by the authors.
Identification and validation of unexposed patients
To determine whether lymphoma has a better prognosis when associated with sarcoidosis, patients with diffuse large B-cell lymphoma (DLBCL) were compared with subjects suffering from DLBCL with no active or past sarcoidosis.
The patients in the unexposed (to sarcoidosis) group were selected from the institutional database of diagnosis coding from among DLBCL cases hospitalized in the University Hospital of Lyon Sud between 1999 and 2013. Each of the 10 DLBCL cases included in the study was matched with three or four unexposed subjects, according to age at diagnosis (10 years), gender, year of diagnosis (10 years), presence and localization of visceral involvements and forms of treatment (type of chemotherapy and use of rituximab).
Collected data
Medical records were reviewed and demographic, clinical and laboratory data were collected by a single investigator (E.C.) using a comprehensive questionnaire. Chest x-rays were rated according to the Scadding criteria. 7 The status of the lymphoma was classified as follows: complete response, partial response, stable disease and progressive disease. 8 
Statistical analysis
In the descriptive cohort study, the data were described as number and percentage for the qualitative variables and as median range from minimum to maximum for the quantitative variables. The time frame for observation ended on 31 August 2013. Event-free survival data were analyzed using the Kaplan-Meier method, and groups were compared using the log-rank test. Conditional logistic regression was used to investigate the relationship between death or progression of the lymphoma and sarcoidosis in the matched cohort study. This was performed with the PROC PHREG of SAS Õ , which uses a discrete logistic model and creates a stratum for each matched set. Odds ratio and 95% confidence interval (CI) were estimated. P values were considered significant when <0.05. The analyses were performed with SAS (version 9Á2).
Results
Descriptive study
Twenty-one patients were included in the descriptive cohort study. The sarcoidosis and lymphoma group included 9 males (43%) and 12 females (57%) ( Table 1 ). The median age at sarcoidosis diagnosis was 48 years (range: 24-68 years), whereas the median age at lymphoma diagnosis was 63 years (range: 25-83 years). At lymphoma diagnosis, sarcoidosis had previously been diagnosed in 14 of the 21 patients (67%). Of these 14 patients, the median time within which lymphoma was diagnosed after the onset of systemic sarcoidosis was 11 years (range: 5-52 years). Sarcoidosis and lymphoma were diagnosed concomitantly (<1 year between the onsets of the two disorders) in five patients (24%), whereas lymphoma preceded sarcoidosis in two patients, with a median time between diagnoses of 5 years (range: 2-8 years). The median duration of follow-up was 11 years (range: 1-53 years). The most frequent extra pulmonary localizations were lymph nodes (n = 3), sarcoids (n = 1) and erythema nodosum (n = 1), liver (n = 2), spleen (n = 2), arthritis and/or arthralgia (n = 5), uveitis (n = 1) and neurosarcoidosis (n = 1).
Clinical presentation
Lymphoma
Hodgkin's lymphoma was diagnosed in three patients and non-Hodgkin's lymphoma in 18 (DLBCL (n = 11), follicular lymphoma (n = 2), chronic lymphocytic leukemia/small lymphocytic lymphoma (n = 2), anaplastic large cell lymphoma ALK + (n = 1), angioimmunoblastic T-cell lymphoma (n = 1) and T-cell prolymphocytic leukemia (n = 1)). Biopsies were performed for all patients and indicated lymphoma lesions in cervical or supraclavicular lymph nodes (n = 6), the stomach (n = 4), inguinal lymph nodes (n = 3), the skin (n = 2), mesenteric lymph nodes (n = 1), axillar lymph nodes (n = 1), the spleen (n = 1), the tonsils (n = 1), the brain (n = 1) and the mediastinal nodes (n = 1). No histological transformation of low malignancy grade lymphoma to a more aggressive non-Hodgkin's lymphoma was identified. The following patient distributions were identified using the Ann Arbor staging system: stage I: three patients, stage II: one patient, stage III: six patients and stage IV: nine patients. Performance status was !2 in 23% of patients, and the mean serum level of b2-microglobuline was 4.3 mg/l (missing data: five patients). At lymphoma diagnosis, an angiotensin-converting enzyme serum assay was performed in five patients, with a result above the normal range for three patients.
Eleven patients underwent 18-flurorodeoxyglucose positron emission computed tomography (18 FDG PET-CT) to select the biopsy sites (6 patients) and/or to monitor the lymphoma treatment (11 patients). The standardized uptake value was reported for two patients. FDG PET-CT was not helpful in discriminate the two disorders (data not shown).
In the DLBCL group, the temporal relationship between the onsets of sarcoidosis and DLBCL was very similar when compared with the other types of lymphomas (DLBCL after sarcoidosis: 62% vs. 67% for other lymphomas; concomitant diagnosis: 15% for DLBCL vs. 24%; lymphoma before sarcoidosis: 8% for DLBCL vs. 10%). The median age of DLBCL patients at sarcoidosis diagnosis was 48 years (vs. 43 years for other lymphomas) and was 64 years at the time of lymphoma onset (vs. 56 years, P = 0.25).
For the five patients with concomitant lymphoma and sarcoidosis, the median age at sarcoidosis onset was lower than that of patients suffering from sarcoidosis before lymphoma (34 years vs. 51 years, P = 0.01). Of these five patients, one died while receiving chemotherapy, while a complete response to treatment was observed in the remaining four.
Treatment and outcome
Sarcoidosis
Fifteen patients received corticosteroids and four patients received immunosuppressive agents: azathioprine (n = 2) and methotrexate (n = 2). Five patients were receiving systemic therapy at lymphoma onset: corticosteroids alone (n = 3), azathioprine (n = 1) and methotrexate (n = 1).
Lymphoma
Lymphoma was treated with chemotherapy ( Table 1 ). The most frequently used regimen was R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) (n = 12). Three patients needed a second treatment due to relapse (n = 2) or because of disease progression (n = 1). Thirteen patients (62%) were alive and in complete response for 5 years or more, with the exception of one. A partial response was observed in two patients (10%) and disease progression occurred in one patient (5%). The evaluation was not performed for four patients, in whom death occurred before the first disease assessment. After a median follow-up of 36 months, death occurred in seven patients (33%), of which four were directly related to lymphoma, two to sepsis and one to a hemothorax.
Pronostic study
Ten patients with DLBCL and sarcoidosis were compared with 36 patients who also suffered from DLBCL but had no active or past sarcoidosis. The two groups were statistically similar in terms of performance status and international prognostic index 9 ( Figure 1 ) but was not statistically significant (P = 0,685).
Discussion
Since Brincker's original publication, the proposed link between sarcoidosis and malignancy remains controversial. 3 The increased risk of nonHodgkin's lymphoma in patients suffering from sarcoidosis is strongly supported by some studies 5, 10, 11 but not by others. 12, 13 The mechanisms underlying an eventual association between the two disorders are unclear.
14 In sarcoidosis, a local cell-mediated immune response induced by unknown antigens and resulting in the activation of CD4+ cells in an environment lacking significant numbers of regulatory CD8+ cells would lead to the formation of granulomas, as cytokines released by the activated lymphocytes react with and stimulate macrophages. Sarcoidosis is associated with a global regulatory T cells subset amplification whose activity would be insufficient to control local inflammation. 15 One consequence of this amplification might be an enhanced proliferation of naïve and effector T cells producing interleukin-2, which also acts as a growth factor for B cells. An IL-2-driven B-cell proliferation might override endogenous regulatory mechanisms, eventually leading to their transformation into malignant B cells. These complex CT computed tomography; PET-CT: positron emission tomography-computed tomography; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; ABVPP: doxorubicin, bleomycin, vinblastine, procarbazine and prednisone; R-FC: rituximab, fludarabine and chloraminophene; DHAP: dexamethasone, cytarabine and cisplatin; VIM 91: etoposide, mitoxantrone and ifosfamide; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP: bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone, procarbazine, vincristine; R-COPADEM: rituximab, cyclophosphamide, vincristine, prednisolone, doxorubicin, folinicacid and methotrexate; R-CYM: rituximab, cytarabine, folinic acid, methotrexate; ACVBP: doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone; BOM: bone marrow biopsy mechanisms may explain the onset of B-cell malignancies that occurs after several years of sarcoidosis. Twenty-five percent of our patients were still receiving sarcoidosis treatment at the time of lymphoma diagnosis. Indeed, as suggested by some authors, immunosuppressive drugs used in sarcoidosis treatment, and still given to patient at the onset of lymphoma, may be carcinogenic and facilitate infection by pro-carcinogenic viruses. They may also be responsible for revealing an underlying hematologic malignancy. 16 The occurrence of sarcoidosis in patients previously treated for lymphoma with antineoplastic agents has also been reported. In these cases, alpha-interferon appears to be the therapeutic agent most often implicated. 4 As observed in other studies, none of our patients received this treatment. 6 In agreement with the published data, sarcoidosis preceded the onset of lymphoma in two-thirds of our cases. 5, 17 The median age at onset of sarcoidosis was 48 years, which is higher than expected for an unselected sarcoidosis population and higher than the age reported in the review by Papanikolaou. 5 The median time between the onset of both disorders was longer in our study (11 years vs. 8 years). 5 Moreover, we estimate that the diagnosis of lymphoma may have been delayed in some patients, the first symptoms of the lymphoma having been mistakenly attributed to a sarcoidosis relapse.
In accordance with a recent report from a German cohort of 425 sarcoidosis patients, non-Hodgkin's lymphomas appear to be more frequent than Hodgkin's lymphomas. 5, 18 The predominance of DLBCL may also be explained by the improvement of histopathological analysis. In our study, patients with concomitant diagnosis were younger at the onset of sarcoidosis than the patients in whom sarcoidosis preceded lymphoma, data which were not reported by Papanikolaou. 5 We found no statistical difference between the temporal relationship between sarcoidosis and DLBCL in our two groups (lymphoma preceding sarcoidosis, lymphoma concomitant to sarcoidosis and sarcoidosis preceding lymphoma).
Excision of peripheral lymph nodes often leads to a positive biopsy. 5 Interestingly, a gastric biopsy confirmed the diagnosis of DLBCL in four of our patients. In accordance with DLBCL data available in the literature, 33% of our DLBCL patients presented with extranodal primary sites, but the frequency of gastrointestinal tract localizations seems higher (57% vs. 34% in the literature). 19 Consequently, faced with a patient suffering from sarcoidosis who presents atypical features (age of onset > 50 years, constitutional symptoms, onset or worsening of splenomegaly or lymphadenopathy), clinicians must think of lymphoma as an alternative or additional diagnosis. Pathologists will thus be required to meticulously examine the whole piece of the biopsy, searching for immuno-histochemical expressions and elements of clonality. On the other hand, faced with a lymphoma patient presenting hilar bilateral lymphadenopathy and respiratory symptoms, the alternative diagnosis of sarcoidosis must be ruled out before the initiation of a potentially toxic chemotherapy. 5 Both lymphoma and sarcoidosis present a high affinity for 18-FDG. However, contrary to previously reports, [20] [21] [22] 18 FDG PET-CT was not helpful in discriminating the two disorders in our series. New radiopharmaceutical probes are currently being developed which could improve this differentiation. 23 Furthermore, diffusion-weighted magnetic resonance imaging seems to be able to differentiate lymphoma from sarcoidosis in mediastinal-hilar lymphadenopathy by means of apparent diffusion coefficients values. 24 Granulomatous reaction has been associated with a better prognosis in some cancers. 25 In our study, a lower rate of events was noted in the sarcoidosislymphoma group compared with the lymphomaalone group. However, this difference was not statistically significant. This trend may also be explained by some false positive findings which led to the misclassification of the lymphoma status and to inappropriate treatment being proposed.
Although this study provides important information, our work has a number of limitations. First, this is a retrospective comparative study, and consequently, some clinical and laboratory data are missing (delay in diagnosis or the level of sarcoidosis activity at lymphoma diagnosis). Moreover, the gene-expression profiling used to define molecular subtypes of DLBCL (germinal centre B-cell-like lymphoma and activated B-cell-like lymphoma 26 ) is not available. Finally, we are aware of the fact that the small number of patients included in this series somewhat compromises the pertinence of the statistical analysis.
Conclusions
Here, we report the largest series of patients presenting both sarcoidosis and lymphoma and the first exposed-unexposed cohort study comparing the prognosis of these patients. We also reported the predominance of DLBCL in sarcoidosis patients. Sarcoidosis did not appear to modify the prognosis of patients with DLBCL. Clinicians should be aware of the potential risk of lymphoma in sarcoidosis patients presenting with new or enlarging lesions, asymmetrical nodes or constitutional symptoms. Less frequently, the onset of sarcoidosis may follow, or even occur concurrently with, the onset of lymphoma, representing another diagnostic challenge.
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